Healthcare >> CEO Interviews >> March 17, 2009
ROBERT T. ABBOTT, President and Chief Executive Officer of OnKor
Pharmaceuticals, Inc., is a serial entrepreneur of the biotech industry. He has
built and led six biotech companies, three of which have become public
companies. His previous positions include President, CEO and a Director of Amkor
Pharmaceuticals, Seattle, Washington, whose principle product was under
development for the treatment of stroke and sudden cardiac arrest; President,
CEO and a Director of Selective Genetics, Inc., a gene therapy company
specializing in tissue repair; President, CEO and Director of Matrigen
Pharmaceuticals, a predecessor to Selective Genetics; President, CEO and a
Director of Angiotech Pharmaceuticals, Inc., developer of the paclitaxol-eluting
coronary stent; President, CEO and a Director of Viagene, Inc., a leading
pioneer in the gene therapy area; and a Founder, President, CEO and a Director
of NeoRx Corporation, a therapeutic monoclonal antibody company. Mr. Abbott
earned a BS in Biochemistry and Genetics and a PhD in Pathology from McGill
University in Montreal, Canada, an MBA in Marketing from the University of
Missouri in St. Louis, and he attended Indiana University School of Law in
Indianapolis for two years before transferring to Seattle where he began
founding companies. Profile
this point?
Mr. Abbott: OnKor is a virtually run company that is in the business of
translational research,
